OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4⁺ T cells

Andreas A. Hombach, Johannes Heiders, Marcel Foppe, Markus Chmielewski and Hinrich Abken*

Center for Molecular Medicine Cologne (CMMC) and Tumor Genetics; Department I Internal Medicine; University of Cologne; Cologne, Germany

Keywords: adoptive cell therapy, chimeric antigen receptor, CD28, IL-10, OX40

Abbreviations: CAR, chimeric antigen receptor; ELISA, enzyme-linked immunosorbent assay; IFN, interferon; MFI, mean fluorescence intensity; scFv, single-chain fragment of variable region antibody; XTT, 2,3-bis(2-methoxy-4-nitro-5-sulphonyl)-5[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide

Adoptive therapy with chimeric antigen receptor (CAR) redirected T cells recently showed remarkable anti-tumor efficacy in early phase clinical trials; self-repression of the immune response by T-cell secreted cytokines, however, is still an issue raising interest to abrogate the secretion of repressive cytokines while preserving the panel of CAR induced pro-inflammatory cytokines. We here revealed that T-cell activation by a CD28-Δsignaling CAR induced IL-10 secretion, which compromises T cell based immunity, along with the release of pro-inflammatory IFNγ and IL-2. T cells stimulated by a ΔCAR without costimulation did not secrete IL-2 or IL-10; the latter, however, could be induced by supplementation with IL-2. Abrogation of CD28-ΔCAR induced IL-2 release by CD28 mutation did not reduce IL-10 secretion indicating that IL-10 can be induced by both a CD28 and an IL-2 mediated pathway. In contrast to the CD28⁻ΔCAR, a CAR with OX40 (CD134) costimulation did not induce IL-10. OX40 co-signaling by a 3rd generation CD28⁻ΔOX40 CAR repressed CD28 induced IL-10 secretion but did not affect the secretion of pro-inflammatory cytokines, T-cell amplification or T-cell mediated cytosis. IL-2 induced IL-10 was also repressed by OX40 co-signaling. OX40 moreover repressed IL-10 secretion by regulatory T cells which are strong IL-10 producers upon activation. Taken together OX40 co-signaling in CAR redirected T cell activation effectively represses IL-10 secretion which contributes to counteract self-repression and provides a rationale to explore OX40 co-signaling CARs in order to prolong a redirected T cell response.

Introduction

Adoptive cell therapy with chimeric antigen receptor (CAR)-redirected T cells showed remarkable anti-tumor efficacy in recent clinical trials. Patients’ T cells are ex vivo engineered with a CAR which redirects the T cell through the extracellular antibody-derived binding domain toward target cells in a major histocompatibility complex (MHC)-independent fashion. CAR intracellular signaling domain, which most frequently is the CD3ζ endodomain derived from the T-cell receptor (TCR) complex, mediates T-cell activation upon target engagement and initiates a plethora of effector functions including the secretion of pro-inflammatory cytokines, cytosis of target cells and amplification of redirected T cells. Both CD8⁺ and CD4⁺ T cells can specifically be redirected by an engineered CAR; both T-cell subsets are required for a potent and sustained anti-tumor response. CAR redirected T-cell activation, however, is short-term when no appropriate costimulation simultaneously to CD3ζ signaling occurs and when target cells lack costimulatory ligands. A costimulatory endodomain like CD28 was therefore fused to the CD3ζ CAR endodomain to prolong T-cell survival and to produce efficient killing, cytokine release and T-cell proliferation. Signaling through the fused CD28 endodomain thereby strengthens the CAR redirected T-cell response through the induction of IL-2 and the increase of IFNγ. Upon CD28 and CD40L TCR mediated activation T cells upregulate “late” costimulatory molecules of the tumor necrosis factor receptor family including 4-1BB (CD137) and OX40 (CD134) which are involved in prolonging T-cell persistence and inducing T-cell memory. For instance OX40 is upregulated 24 h after antigen engagement in presence of CD28 costimulation and further augments CD28 activated T-cell responses with respect to proliferation, cytokine responses and survival. Several lines of evidences imply that the success of a redirected T-cell therapy of cancer depends on the maintenance of T cell effector functions in the long-term which can be ensured by integrating the primary TCR and CD28 signal with late costimulatory signals. Consequently, Pule et al. hypothesized that the combination of
CD28 and OX40 endodomains in cis with CD3ζ in a CAR will improve redirected T-cell effector functions and enhance anti-tumor activity. The T-cell response is physiologically limited by various mechanisms, one of which are repressive cytokines like IL-10 which are present in high concentrations in the tumor microenvironment, are produced by both tumor and stroma cells and which impair an anti-tumor response.16 CD28 costimulation of T cells also induces IL-10 secretion17 which in turn compromises T-cell based immunity through downregulation of MHC molecules,19 the CD28 ligands CD80 and CD86 and of the intercellular adhesion molecule-1 (ICAM-1) on antigen-presenting cells (APCs).20,21 As a consequence the antigen-driven T-cell amplification is turned off, the secretion of pro-inflammatory cytokines is repressed and anti-inflammatory cytokines are released which contribute to a further polarization of the immune response. In addition to effector T cells, CD4+ regulatory T (Treg) cells are potent IL-10 producers moreover repressing the T-cell attack.22 Adoptive T-cell therapy of cancer aims to tip the balance by promoting T-cell activation while reducing repression, both contributing to the overall therapeutic success. We here revealed that (1) CD28-ζ CAR redirected T cells upregulate IL-10 secretion upon antigen engagement, (2) IL-10 is also induced when ζ CAR T cells are activated in presence of IL-2, and (3) that IL-10 induced by either mechanism can be abrogated by co-signaling through OX40 in both CD4+ helper and regulatory T cells. Consequently, combined signaling through a CD28-ζ CAR repleted IL-10 without affecting the other T-cell effector functions like secretion of pro-inflammatory cytokines. We assume such dual costimulatory CAR of benefit in improving T-cell anti-tumor immunity in long-term.

**Results**

We screened the cytokine profiles of CAR redirected human CD4+ T cells upon engagement of CAR-defined antigen. While the CARs have the same extracellular binding domain for carcinoembryonic antigen (CEA), the signaling moiety is composed of the CD3ζ endodomain fused to the intracellular CD28 or OX40 chain, respectively, providing different costimuli (Fig. 1A). Upon retroviral transduction, CARs were expressed on the surface of human T cells with nearly same efficiencies (Fig. 1B). A CD3ζ CAR without costimulatory domain was expressed in CD4+ T cells for comparison. Engineered T cells were co-incubated with CEA+ and CEA- tumor cells, respectively, to record CAR-driven T-cell activation. Engineered T cells were activated to secrete IFNγ upon co-incubation with CEA+ but not with CEA tumor cells demonstrating the specificity of CAR mediated T-cell activation (Fig. 2A). IFNγ secretion was substantially enhanced by CD28 and OX40 costimulation, respectively. IL-2, however, is secreted only upon CD28 co-stimulation. T-cell amplification was most effectively induced by the CD28ζ CAR and less by ζ and ζOX40 CAR stimulation (Fig. 2B). CD28ζ CAR engagement moreover induced secretion of IL-10 in high levels which were much lower without ζCD28 or with OX40 costimulation. Since CD28 costimulation in contrast to OX40 additionally induced IL-2, we asked whether IL-10 secretion is induced by IL-2 independently of costimulation. To address the question in a thoroughly controlled setting, ζ CAR engineered T cells were specifically stimulated by the immobilized anti-idiotypic antibody BW2064, which is directed toward the scFv CAR domain, in presence or absence of added IL-2. As shown in Figure 3,
IL-2 enhanced, along with IFNγ, IL-10 secretion of ζ CAR engineered T cells upon CAR engagement with antigen. IL-2 did not induce IL-10 secretion, however, when T cells were stimulated by the OX40ζ CAR. As controls IL-2 increased IL-10 secretion by CD28ζ CAR modified T cells whereas IL-2 did not induce IL-10 in non-modified T cells without stimulation. Taken together, IL-2 in the context of ζ CAR signaling induced IL-10 which is not the case in presence of OX40 costimulation.

Since CD28ζ CAR signaling induced IL-2 secretion we asked whether IL-10 secretion is due to autocrine acting IL-2 upon CD28 mediated release. We abrogated IL-2 release by abrogating lck binding to CD28 by mutation of the lck binding motif in the CAR CD28 signaling moiety. CD4+ T cells were engineered with the mutated CD28ζζ CAR or for comparison with the ζζ and CD28ζζζζ CAR, respectively, and stimulated through binding to the CAR antigen. As summarized in Figure 4, the CD28ζζζζ CAR did not induce IL-2 secretion while IL-10 and IFNγ secretion are not altered compared with the wild-type CD28ζζζζ CAR. Cytokine secretion was specifically induced by CAR engagement of antigen because coincubation with an irrelevant antigen did not induce IL-10 secretion. Data indicate that at least two pathways can induce IL-10 secretion in CAR engineered T cells, one via IL-2 and the other via CD28 independently of IL-2 induction.

Figure 2. CD28ζζζζ CAR induces IL-10 secretion by engineered T cells. CD4+ T cells were engineered with the anti-CEA CAR and (A) coincubated (1.25 x 10^5–1 x 10^6 CAR T cells/well) for 48 h with CEA+ LS174T or CEA+ Colo320 tumor cells (each 2.5 x 10^4 cells/well) or (B) incubated (2.5 x 10^4/well) in microtiter plates that were coated with 10 μg/ml of the CAR-specific anti-idiotypic mAb BW2064 which binds to the CAR BW431/26 scFv domain to specifically stimulate CAR T cells, or an isotype control mAb (IgG1). The number of CAR expressing T cells was adjusted to equal numbers by adding non-transduced cells from the same donor. Cytokines in the supernatant were recorded by ELISA, proliferation was determined by BrdU incorporation. Data represent the mean of triplicates ± standard error of the mean (SEM).
Since \(\Delta\)OX40 CAR redirected T cells did not produce IL-10 in presence of added IL-2, we asked whether OX40 costimulation prevents CD28 mediated IL-10 secretion. To address the issue, we made use of a CD28-\(\Delta\)OX40 dual costimulatory CAR. For comparison, we used a CD28\(f\) and CD28\(\Delta\)OX40 CAR which were deficient in IL-2 induction. CARs were expressed in CD4\(+\) T cells and triggered by immobilized, CAR-specific antibody. As summarized in Figure 5, CD28\(f\) CAR T cells did not secrete IL-10 when costimulated by OX40. IL-10 is also repressed in presence of OX40 co-signaling when T cells were stimulated by the mutated CD28\(\Delta\alpha\) CAR. For comparison, all CARs induced similar amounts of secreted IFN\(\gamma\) indicating a similar T cell activation potency. IL-2 is secreted upon CD28\(f\) and CD28\(\Delta\alpha\) signaling indicating the functional integrity of the CD28 domain while IL-2 is not induced by the mutant CD28\(\Delta\alpha\) and the CD28\(\Delta\alpha\)OX40 CAR as expected. In summary, data indicate that OX40 in a combined CD28-\(\Delta\alpha\)OX40 CAR repressed CD28 induced IL-10 secretion by redirected T cells.

Treg cells are strong producers of IL-10. We therefore asked whether CAR mediated OX40 co-signaling does also repress IL-10 secretion by Treg cells. Human CD4\(+\)CD25\(+\) IL-7R\(-\) T cells were isolated from the peripheral blood (Fig. 6A). Cells were activated and expanded as recently described.\(^{23}\) Expanded cells were verified as Treg cells by a standard suppressor assay (Fig. 6B). We engineered Treg cells with CD28\(f\) and...
CD28OX40 CARs with similar efficiencies (Fig. 6C). Upon CD28f and CD28OX40 CAR redirected activation, Treg cells secreted same amounts of IFNγ indicating a similar degree in CAR mediated activation (Fig. 6D). No IL-2 is induced as expected for Treg cells. CD28f CAR modified Treg cells, however, secreted high amounts of IL-10 which were substantially reduced when redirected by the CD28OX40 CAR. Data indicate that OX40 costimulation as provided by a CD28OX40 CAR repressed IL-10 secretion in Treg cells as it did in effector T cells.

Discussion

We here demonstrate that CD28f CAR redirected T cells secrete high amounts of IL-10 which is also the case when δ CAR T cells were stimulated in presence of IL-2. Since CD28Δδ CAR T cells which do not produce IL-2 upon CAR engagement still secrete IL-10 we conclude that IL-10 secretion by activated T cells can be induced by CD28 costimulation independently of IL-2 signaling. Simultaneous OX40 costimulation by a CAR repressed both IL-2 and CD28 mediated IL-10 secretion. IL-10 repression was not
Figure 6. For figure legend, see page 464.
due to an impaired overall signaling because IFN-γ and IL-2 secretion were not altered by OX40 costimulation.

Endomodules from single costimulatory molecules linked to CD3ζ in a CAR are sufficient to activate the killing machinery and to increase T-cell proliferation and IFN-γ release.24 OX40 and 4-1BB CARs less enhance T cell proliferation when inserted in cis as a CAR compared with a CD28-CAR.25 OX40 co-signaling did not substantially increase the cytolytic activity and T cell amplification. While CD3ζ CAR T cells fail to sustain their function in the long-term, T cells redirected by the CD28- OX40 CAR produced lasting anti-tumor activity in a xenograft metastatic model.26-28 CD28-OX40 redirected T cells, however, were unable to completely eradicate the disease which may be due in part to insufficiently sustaining human T cell function in the mouse. We assume that the combined CD28-OX40 CAR significantly increases the expansion of naïve T cells in absence of the appropriate ligands on target cells or APCs. While CD28 activation initiates clonal expansion of naïve T cells and IL-2 secretion, in the absence of additional cooperative signals only a small number of antigen-responding T cells persist and the majority of T cells undergo apoptosis.26 In this context fusion of the “late” costimulatory OX40 signal in cis to the CD28 “early” signal in a combined CAR will be of benefit compared with OX40 or CD28 costimulation only. Consequently, incorporation of the OX40 signaling domain favors the expansion, persistence and effector functions of those cells27 which likely occurs because both costimulatory domains produce greater activation of NFκB than either domain alone. CD28 and OX40 activate NFκB by different pathways, i.e., CD28 via Vav and PI3K and OX40 via TRAF2. NFκB independent signals via Akt and API are additionally transmitted.29,30

The different costimulatory CARs produce different patterns of secreted cytokines. CD28ζ CAR T cells in particular produce IL-2 and IL-10 which both were not secreted by OX40 CAR T cells.27 T cells redirected by the CD28-OX40 CAR produced IL-2 and increased IFN-γ after stimulation which is in accordance to previous reports.26 The CD28ζ CAR which did not produce IL-2 due to the mutated 1k binding domain in the CD28 signaling moiety displays a more favorable panel of secreted cytokines with high IFN-γ levels without providing IL-2 supporting Treg cell survival and repression.28 Proliferation of engineered effector T cells is likewise sustained by the modified CAR. Pule et al.31 reported that CD3ζ and OX40ζ CAR T cells did not produce IL-10, which is in accordance to our observation, CD28-OX40 CAR T cells, however, were found to secrete IL-10 in nearly the same but hardly detectable levels as CD28 CAR T cells. The divergent observation may be due to the different arrangement of the signaling domains in cis described in the Pule report,31,32 i.e., a CAR with CD28 followed by OX40 followed by CD3ζ whereas we used a CAR with OX40 in a terminal position. Both CARs have CD28 in a membrane proximal position and have the same trans-membrane domain which determines the level of surface CAR expression.33,34 Both CARs in which CD28 is merely membrane distal are not functional in CD3ζ costimulation.35,36CARs with CD28 trans-membrane domain show higher expression on the T-cell surface than CARs with a CD3ζ membrane domain which is in accordance to Pule et al.15

Combining “early” with “late” costimulatory signals in cis in a CAR, however, has its limitation since it does not completely recapitulate the temporal-spatial signaling events as they physiologically occur to sustain T-cell activation.27 Repression of IL-10 by signaling through a CD28-CAR-OX40 CAR likely prevents autoimmune suppression of CAR redirected T cells through a prolonged cellular immune response. IL-10 repression will moreover be of interest when combining the “T-body” approach with vaccination against tumor associated antigens29 and prevent accumulation of IL-10 in the tumor microenvironment that in turn may compromise the anti-tumor response.30 There may be concerns to transduce T cells by a retrovirus with a CAR and strong and lasting proliferative signals. Retroviral integration potentially can induce T cell acute lymphoblastic leukemia due to LMO2 overexpression in patients with X-linked severe combined immunodeficiency who received hematopoietic stem cells engineered to constitutively express the common γ-chain receptor.35 In contrast to retroviral modification of hematopoietic stem cells, engineering mature T cells in experimental models did not or very rarely result in malignant transformation.36,37

Materials and Methods

Cell lines and reagents. 293T cells are human embryonic kidney cells that express the SV40 large T antigen.36 The CEA-expressing colon carcinoma cell line LS174T (ATCC CCL 188) and the CEA-negative cell line Colo320 (ATCC CCL 220.1) were obtained from ATCC. The anti-CEA mAb BW431/26 and the anti-id mAb BW2064/36 with specificity for the anti-CEA

Figure 6 (See opposite page). IL-10 secretion was repressed in CD28/OX40 CAR redirected Treg cells. (A) Isolation of CD4+CD25-IL-7R- regulatory T cells from peripheral blood by MACS procedures, isolated Treg cells were incubated with the costimulatory OX40-FITC, anti-CD25-PE and anti-CD4-APC mAbs, respectively, and analyzed by flow cytometry. (B) Isolated T reg cells were activated and expanded in the presence of IL-2 (1,000 U/ml) on solid phase bound agonistic anti-CD3 and anti-CD28 mAbs (each 10 μg/ml). Cells were rested for 48 h without stimul and tested for suppressor activity. Allogeneic, CD40 responder cells (1 × 10⁶ cells/well) and Treg cells (1 × 10⁵ cells/well) were cocultivated for 5 days in the presence or absence of agonistic anti-CD3 (10 μg/ml) and anti-CD28 (1 μg/ml) antibodies, pulsed with BrDU and proliferation determined by a cell ELISA. (C) CD4+CD25- OX40 regulatory T cells express CARs with high efficacy. Isolated CD4+CD25-IL-7R- regulatory T cells were retrovirally transduced to express the anti-CEA CARs which harbor either the CD28ζ or CD28/OX40 signaling domain. CAR engineered T cells were detected by a PE-conjugated anti-human IgG antibody and analyzed by flow cytometry. (D) Sera dilution of the anti-idiotypic mAb BW2064 were coated on microtiter plates (0.1-10 μg/ml). CD4+CD25-IL-7R- T cells were engineered with the CD28ζ or CD28-OX40-COX40 CAR, respectively, adjusted to equal numbers of CAR expressing cells and incubated for 48 h in coated microtiter plates (1 × 10⁵ CAR T cells/well). Culture supernatants were recorded by ELISA for IFN-γ, IL-2 and IL-10, respectively. The assays were performed three times; data represent mean values of triplicates ± SEM of a representative experiment.
mAb BW431/26 were described earlier.70, 71 OKT3 (ATCC CRL 8001) is a hybridoma cell line that produces the anti-CD3 mAb OKT3. All cell lines were cultured in RPMI 1640 medium, 10% (v/v) FCS (all Life Technologies). OKT3 mAb was affinity purified from hybridoma supernatants utilizing goat anti-mouse IgG2a antibodies (Southern Biotechnology) that were immobilized on N-hydroxy-succinimimid-ester-(NHS)-activated sepharose as recommended by the manufacturer (Amersham Biosciences). The goat anti-human IgG antibody and its biotin-, FITC- or PE-conjugated anti-mouse IgG antibodies were purchased from Southern Biotechnology. The anti-IFNγ mAb NB42 and the biotinylated anti-IFNγ mAb 4S.B3, the anti-IL-2 mAb 5344.111 and the biotinylated anti-IL-2 mAb B-3-2, and the anti-human IL-10 mAb 4D5 and the biotinylated anti-human IL-10 mAb 6D4/166/G2 were all purchased from BD Biosience.

Generation and expression of recombinant anti-CEA CARs. The generation of the retroviral expression cassettes for the cytometric analyses. Isolation, propagation and retroviral gene were isolated by magnetic activated cell sorting (MACS) utilizing www.landesbioscience.com OncoImmunology 465 detail elsewhere; 36, 38 CAR expression was monitored by flow Retroviral transduction of T cells with CARs was described in (1,100 U/ml) in microplate Fortran Program of the Medical Faculty of the University of

Acknowledgments

This study was supported by grants from the Deutsche Krebshilfe, Bonn, the Wilhelm Sander-Stiftung, München, and the Köln Fortune Program of the Medical Faculty of the University of Cologne, Cologne, Germany.

References

1. Kahn M, Levine RL, Porter DL, Katz A, Grupp SA, Bachi A, et al. T cells with chimeric-antigen receptors have potent antitumor efficacy and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3(9):32ra7, PMID31205338, http://dx.doi.org/10.1126/scitranslmed.3002842
2. Eichler Z, Wake T, Grune G, Schadde DG. Specific activation and targeting of systemic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the CD3 delta chain and T-cell receptors. Proc Natl Acad Sci U S A 1993; 90(20):8361-6, PMID8361771, http://dx.doi.org/10.1073/pnas.90.2.720
3. Wahler S, Korda D, Dessimio D, Caramas R, Wermuth JA, Toprani JA, Smith MJ, et al. Simulated antigen-specific, antitumor recall response mediated by gene-modified CD4+ T helper 1 and CD8+ T cells. Cancer Res 2007; 67:11428-37, PMID17950647, http://dx.doi.org/10.1158/0008-5472.CAN-07-1141
4. Hennecke A, Sore H, Schindler C, Hoener C, Kordes D, Nak C, et al. T-cell activation by chimeric receptor CD28 cotransduction is required for inter- luminal 2, secretion and receptor-mediated T-cell pro- liferation but does not affect receptor-mediated target cell lysis. Cancer Res 2001; 61:6776-82, PMID11488755
5. Snary HM, Albiez AM, Lamers ADG. Activation of resting human primary T cells with chimeric-antigen-receptor CD28, interleukin-2, or CD80/CD86 in vitro with signals from the B7-1/CD28 axis. J Immunol 2004; 173:5944-51, PMID15528328
6. Weller S, Pace G, Testa J, Davies L, Juretschko S, Cooper L, et al. Reengineering of human T cells to tumor- associated MUC1: the evolution of a chimeric antigen receptor. Cancer Gene Ther 2006; 13:89-99, PMID1634214
7. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui C-H, Geiger TL, et al. Chimeric receptors with 4-1BB and OX40 signaling capacity provoke potent cytotoxicity against auto- lymphoma leukemia. Leukemia 2004; 18:767-76, PMID15098105, http://dx.doi.org/10.1038/sj.leu.2202582
8. Sohulus L, Bokószely P, Weis T, Wang C, Remy J-P, Brandslund MR, et al. Evaluation of OX40 Ligand as a co-stimulant of human antiviral memory CD8 T cell responses in comparison with 4-1BBL and 4-1BB. J Immunol 2004; 173:6366-71, PMID15272289

www.landesbioscience.com OncolImmunology 465

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
18. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 2008; 180:5771-7; PMID:18424693

19. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, Te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and its receptor. J Exp Med 1991; 174:915-24; PMID:1655948; http://dx.doi.org/10.1084/jem.174.4.915

20. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of antisense IL-10 on dendritic cell functions. J Immunol 2001; 166:4312-8; PMID:11488054; http://dx.doi.org/10.1111/j.1365-2567.2001.00851.x

21. Fei Y, Donnarumma R, Garuram K, Herberman R, Glatzer L, Martin S, et al. In situ depletion of regulatory T cells by recombinant immunoreceptors: CD3 zeta signaling in dendritic cells. J Immunol 2007; 165:3043-50; PMID:10975814

22. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Hawkins RE, Stern PL. Combination of vaccination and cytokine delivery: a novel strategy for adoptive T cell therapy of tumors. J Immunol 2006; 177:5817-24; PMID:16930627; http://dx.doi.org/10.1111/j.1365-2179.2006.01565.x

23. Hombach AA, Raffel D, Rappl G, Hoffman HD, Hombach A. Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood to preclinical tumor xenografts. J Immunother 2008; 31:384-90; PMID:18354595; http://dx.doi.org/10.1097/01.jio.0000289670.07629.9f

24. Giannelli L, Jablonski A, Pipping KD, Workhorse AD, Klukow N, Corbelli M. The CD40/CD154 costimulatory receptor: development of a CD40 research reagent. J Immunol 2011; 186:1780-7; PMID:21973985; http://dx.doi.org/10.4049/jimmunol.1003602

25. Rusi T, Tonni M, Tanneyk V, Morovic MT, Biljanova SD. Induction of T cell responses against tumor Ags using recombinant DNA vaccines in vivo. J Immunother 2010; 33:381-90; PMID:20975555; http://dx.doi.org/10.1002/jimm.20930

26. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Martin C, Dippold W. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell expression and T cell activation: pleiotropic pathways down-regulating primary clonal expansion. J Immunol 1998; 161:2791-7; PMID:9619546; http://dx.doi.org/10.1111/j.1556-9862.1997.tb00127.x

27. Pule MA, Savoldo B, Myers GD, Rossig C, Russell ML, Jr., Greenfield EA, et al. Ox40-ligand has a critical role in preventing Lck activation. Mol Ther 2011; 19:760-6; PMID:21326215; http://dx.doi.org/10.1038/mt.2010.223

28. Kane LP, Weiss A. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways down-regulating primary clonal expansion. J Immunol 2008; 180:5771-7; PMID:18424693

29. Hombach AA, Raffel D, Rappl G, Hoffman HD, Hombach A. Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood to preclinical tumor xenografts. J Immunother 2008; 31:384-90; PMID:18354595; http://dx.doi.org/10.1002/jimm.20930

30. Bridgeman JS, Hawkins RE, Hombach AA, Marquardt T, Heuser J, Aretz U. A retroviral vector system in combination with an optimized single chain antibody chimeric antigen receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Therapy 2009; 16:1595-606; PMID:19554546; http://dx.doi.org/10.1038/sj.gt.3301879

31. Finney HM, Lawson AD, Bebbington CR, Weir AN. Ox40: a T cell activation marker that may mediate immune evasion by melanoma cells. J Immunother 2003; 26:465-9; PMID:1274813

32. Jiang H-R, Gilham DE, Mulryan K, Kirillova N, McCracken MP, Wulffraat N, Leboulch P, et al. LM02-associated clonal T cell proliferation in patients after gene therapy for SCID-X1. Science 2003; 302:415-9; PMID:14564000; http://dx.doi.org/10.1126/science.1088547

33. van Loons E, Fiers M, Taatjes D, Irimia D, Vojnovic B, Roux C, Schlo A, et al. Transfer of an optimizing gene-modified T cell in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Nat Med 2007; 13:1024-33; PMID:17583641

34. Norwals S, Condi K, Heiman T, Maier J, 1-3141, Lymanski O, et al. Reversal of metastatic cancer can contribute to immunisation of patients to lymphocytic Med. J Med Publ. (Online First) 2011; 27

35. Wittmann MI, Willmsen BA, Hart CH, Becklin RI. A universal vector system "STITCH" in combination with an optimized single chain antibody chimeric antigen receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Therapy 1998, 5:1109-23; PMID:9930538; http://dx.doi.org/10.1038/sj.gt.3301879

36. Kajston H, Sonnemans G, Boulter K, Schrauw D, Depuydt W. Humanized anti-carcinoembryonic antigen antibody, strategies to enhance human tumor cell killing. Nat Immunol 1998; 7:74-82; PMID:9723459

37. Hombach AA, Wuzniczekova A, Maripuu H, Jaslan C, U USA I, Dali C, et al. Tim-3-specific T cell activation by recombinant immunomodulatory CD3 zeta signaling and CD28 costimulation is insufficiently required for efficient IL-2 secretion and can be integrated into one combined CD3/CD28 zeta signaling product. J Immunol 2009; 187:6123-31; PMID:19717471